This article was originally published in The Gray Sheet
Diatide AcuTect: Company receives an approvable letter Feb. 20 for use of the imaging agent in treating acute venothrombosis in lower extremities. The firm anticipates a third quarter launch to the radiopharmacy community via a 10-person sales force. Diatide's marketing partner, Nycomed, will market AcuTect to physicians, hospitals and preferred provider organizations. The imaging drug was recommended for approval by FDA's Medical Imaging Drugs Advisory Committee on Feb. 9 ("The Gray Sheet" Feb. 16, I&W-15)...
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.